These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11242632)

  • 1. [Molecule targeted therapy for hematological malignancies].
    Naoe T
    Gan To Kagaku Ryoho; 2001 Feb; 28(2):131-4. PubMed ID: 11242632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based therapy for leukemia: a lesson from ATRA therapy.
    Naoe T
    Nagoya J Med Sci; 2001 Nov; 64(3-4):103-8. PubMed ID: 11820331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets and the treatment of myeloid leukemia.
    Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
    Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.
    Naeem M; Harrison K; Barton K; Nand S; Alkan S
    Eur J Haematol; 2006 Feb; 76(2):164-6. PubMed ID: 16405439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Arsenic and retinoic acid, towards targeted treatments of acute promyelocytic leukemia?].
    de Thé H
    Bull Acad Natl Med; 1998; 182(1):63-71. PubMed ID: 9622932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.
    Raza S; Ullah K; Ahmed P; Khan B
    J Coll Physicians Surg Pak; 2008 Sep; 18(9):546-50. PubMed ID: 18803891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application.
    Wang Z; Sun G; Shen Z; Chen S; Chen Z
    Chin Med J (Engl); 1999 Nov; 112(11):963-7. PubMed ID: 11721474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All trans retinoic acid.
    Advani SH
    J Assoc Physicians India; 1995; Suppl 3():65-6. PubMed ID: 8773125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoic acid receptors, hematopoiesis and leukemogenesis.
    Collins SJ
    Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.
    Padua RA; Larghero J; Robin M; le Pogam C; Schlageter MH; Muszlak S; Fric J; West R; Rousselot P; Phan TH; Mudde L; Teisserenc H; Carpentier AF; Kogan S; Degos L; Pla M; Bishop JM; Stevenson F; Charron D; Chomienne C
    Nat Med; 2003 Nov; 9(11):1413-7. PubMed ID: 14566333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of all-trans retinoic acid with butyric acid and its prodrugs markedly enhancing differentiation of human acute promyelocytic leukemia NB4 cells.
    Chen Z; Wang W; Pan J; Chen L; Xue Y
    Chin Med J (Engl); 1999 Apr; 112(4):352-5. PubMed ID: 11593538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia.
    Meani N; Minardi S; Licciulli S; Gelmetti V; Coco FL; Nervi C; Pelicci PG; Müller H; Alcalay M
    Oncogene; 2005 May; 24(20):3358-68. PubMed ID: 15735696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.
    Barbarroja N; Siendones E; Torres LA; Luque MJ; Martinez JM; Dorado G; Velasco F; Torres A; López-Pedrera C
    Br J Haematol; 2008 Jul; 142(1):27-35. PubMed ID: 18445086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Leukemogenesis and therapy of acute promyelocytic leukemia: from the worse to the most favorable subtype of acute myeloid leukemia].
    Korístek Z; Mayer J
    Vnitr Lek; 2008; 54(7-8):701-27. PubMed ID: 18780571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curative therapeutic approaches to APL.
    Tallmann MS
    Ann Hematol; 2004; 83 Suppl 1():S81-2. PubMed ID: 15124685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.
    Hu J; Zhou GB; Wang ZY; Chen SJ; Chen Z
    Adv Cancer Res; 2007; 98():191-220. PubMed ID: 17433911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
    Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
    Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.